TransMedics Group (TMDX)
(Delayed Data from NSDQ)
$138.97 USD
-4.83 (-3.36%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $140.00 +1.03 (0.74%) 7:58 PM ET
1-Strong Buy of 5 1
F Value B Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$138.97 USD
-4.83 (-3.36%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $140.00 +1.03 (0.74%) 7:58 PM ET
1-Strong Buy of 5 1
F Value B Growth A Momentum B VGM
Zacks News
Reasons to Retain ResMed Stock in Your Portfolio for Now
by Zacks Equity Research
Strong demand for RMD's market-leading mask portfolio raises investors' optimism.
Will Trinity Biotech Stock Gain From Its Latest Patent Process?
by Zacks Equity Research
TRIB announces updates on its European patented process. The company aims to use this process to improve the functionality of its glucose biosensor in its next-gen CGM technology.
PBH Stock Might Get a Boost From Focused Brand-Building Efforts
by Zacks Equity Research
Prestige Consumer puts emphasis on brand building and product innovation in niche consumer healthcare categories to improve the lives of its consumers.
Can HITI Stock Get a Boost From Bricks-and-Mortar Sales in Q3 Earnings?
by Zacks Equity Research
Given High Tide's progress in executing its strategic initiatives, we expect it to report robust Q3 bricks-and-mortar segment sales.
Will Paragon 28 Stock Gain From the Latest Product Launch of R3FLEX?
by Zacks Equity Research
FNA recently introduced the R3FLEX Stabilization System, whose design should allow surgeons to restore a patient's soft tissue to a more natural anatomy.
Here's Why VCYT Stock Could be a Great Addition to Your Portfolio Now
by Zacks Equity Research
Veracyte looks poised to deliver robust performance owing to its progress with key drivers and the strength in its diagnostics tests.
Align Technology Stock Dips on Macroeconomic Issues, FX Headwind
by Zacks Equity Research
ALGN is facing a decline in Invisalign ASPs for comprehensive treatment options. This is resulting in a decline in the company's revenues.
Abbott's Lingo CGM System Gains U.S. Availability: Stock to Gain?
by Zacks Equity Research
ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who are not on insulin.
QIAGEN Stock Likely to Gain on Collaboration for APOE Genotyping
by Zacks Equity Research
QGEN collaborates with Eli Lilly to develop a QIAstat-Dx IVD panel for APOE genotyping.
Should You Continue to Retain ABT Stock in Your Portfolio Now?
by Zacks Equity Research
Abbott's robust strength in Core Diagnostics and EPD businesses should continue to benefit in the upcoming quarters.
New Partnerships to Aid Myriad Genetics Stock Amid Macro Issues
by Zacks Equity Research
MYGN focuses on effective capital deployment in key areas, including new tech-enabled tools and capabilities, innovation and commercial capabilities.
Reasons to Retain STERIS Stock in Your Portfolio for Now
by Zacks Equity Research
STE's strong prospects in the healthcare business arm bode well for investors.
Zynex Stock Rises on FDA Clearance of Its New Pain Management Device
by Zacks Equity Research
ZYXI recently received the Food and Drug Administration clearance for its new TensWave device. TensWave is designed to provide a comprehensive pain management solution.
Should You Consider Retaining ZBH Stock in Your Portfolio Now?
by Zacks Equity Research
Zimmer Biomet's robust efforts to expand the Knee business and a gradually stabilizing musculoskeletal market appear promising.
Should You Continue to Retain PODD Stock in Your Portfolio Now?
by Zacks Equity Research
Insulet's Omnipod 5 is set to drive growth in the upcoming quarters. Meanwhile, the stock is facing challenges due to economic uncertainties.
Favorable VLA15 Phase 2 Study Results Might Boost VALN Stock
by Zacks Equity Research
Valneva and Pfizer report positive immunogenicity and safety data from their Phase 2 study of the VLA15 vaccine. Phase 3 trials for VLA15 are in progress.
Reasons to Hold Tandem Diabetes Stock in Your Portfolio Now
by Zacks Equity Research
Innovations and a robust diabetes market outlook raise investors' optimism for TNDM.
Dorsata's Alliance on Adnexal Masses to Support Aspira Stock
by Zacks Equity Research
AWH's partnership with Dorsata is set to help with the adnexal masses diagnosis and treatment.
Favorable Clinical Results for HYLA Sensor Might Boost Inspira Stock
by Zacks Equity Research
IINN plans to report clinical results for its new HYLA blood sensor in open-heart surgery patients in the fourth quarter of 2024.
Cellectar Biosciences to Present at IWWM Featuring Iopofosine I 131
by Zacks Equity Research
CLRB announces two presentations featuring its Iopofosine I 131 at the 12th IWWM, in Prague. Jorge Castillo will be the presenter.
Should You Consider Retaining Bruker Stock in Your Portfolio Now?
by Zacks Equity Research
BRKR's robust growth potential across its major segments is encouraging. Yet, macro woes and competitive pressure can pose challenges.
TransMedics (TMDX) Is Up 3.16% in One Week: What You Should Know
by Zacks Equity Research
Does TransMedics (TMDX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Market Share Gains Aid Zimmer Biomet Stock Amid Cost Pressure
by Zacks Equity Research
In terms of Persona cementless Knee, ZBH is currently witnessing strong uptake of the cementless platform Persona OsseoTi.
New Launches Support Tandem Diabetes Stock Despite Macro Concerns
by Zacks Equity Research
The latest addition to TNDM's pump platform portfolio, Tandem Mobi, is leading the way in creating a whole new category of devices for insulin therapy.
Phibro Q4 Earnings and Revenues Beat, Operating Margin Down
by Zacks Equity Research
PAHC's impressive fourth-quarter fiscal 2024 results can be attributed to the Animal Health segment's robust performance.